Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Cancer Res. 2011 Jul 20;71(18):5965–5975. doi: 10.1158/0008-5472.CAN-11-0445

Figure 1.

Figure 1

(A) The quantitative output of the TIMM approach in EBC-1 and HCC827cells subjected to the indicated conditions. Cells were treated with the indicated drugs and ligands for 6 hours before lysis. The relative signal level of each detected adaptor (normalized for p85 levels) is shown. (B) EBC-1 cells were treated in the absence or presence of the MET inhibitor, PHA-665,752 (1µM) for 6 hours and then subjected to lysis. (C) HCC827 cells were treated in the absence or presence of gefitinib (1µM) and HGF (50 ng/mL) for 6 hours. Left) Whole cell extracts were probed with the indicated antibodies. Right) Extracts were subjected to a p85 IP, and the IP was probed with an anti-PTyr and anti-p85 antibodies.